-- （已更新，包含上海证券交易所代码） 药明康德（HKG:2359，SHA:603259）周一在香港联交所提交的公告显示，2026年第一季度归属于母公司股东的净利润为46.5亿元人民币，较上年同期的36.7亿元人民币增长27%。 每股收益为1.58元人民币，高于上年同期的1.28元人民币。 数据显示，营收同比增长29%，达到124.4亿元人民币。
Related Articles
Asia
Syntara Receives Positive US FDA Feedback for Clinical Trial of Bone Marrow Cancer Treatment
Syntara (ASX:SNT) received positive feedback from the US Food and Drug Administration following a type C meeting, supporting the design of its planned phase 2b clinical trial of amsulostat for the treatment of myelofibrosis, according to a Tuesday filing with the Australian bourse.The primary endpoint of the phase 2b study will be the achievement of a 50% reduction in the total symptom score following nine months of treatment, with about 100 patients expected to be enrolled, per the filing.The positive feedback from the US FDA allows for amsulostat's progression into late-stage clinical development and paves the way for further engagement with prospective commercial partners, the company said.Myelofibrosis is a type of bone marrow cancer where the accumulation of scar tissue leads to a loss of red and white blood cells and platelets.
$ASX:SNT
Asia
Market Chatter: Japan IPO Market Will Stay Subdued as AI Stocks Draw Investors
Japan's IPO market will remain under pressure despite strong debuts from a sake brewer and a pet food maker, as investors continue to favor AI-related stocks, Reuters reported Tuesday.Shares of Umenoyado Brewery (TYO:559A) rose about 75% on their first trading day, while Inuneko-Seikatsu (TYO:556A) gained more than 30% after listing. The gains contrast with broader weakness, with many new listings trading below their offer prices this year, the report said.Investor focus on AI leaders such as SoftBank Group (TYO:9984) and Advantest (TYO:6857) has diverted flows away from smaller, domestically focused IPO candidates. Stricter listing standards from the Tokyo Stock Exchange are also weighing on activity, with companies facing tougher valuation thresholds in coming years, according to the report.The number of IPOs in Tokyo will likely fall about 20% this year from 2025 levels, as retail investors prioritize short-term gains in large-cap technology stocks over new listings, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
$^N225$TYO:556A$TYO:559A$TYO:6857$TYO:9984
Asia
Magma Group Completes Private Placement of Shares
Magma Group (KLSE:MAGMA) completed the listing and quotation of 18.9 million shares on the Main Market of Bursa Securities, according to a Monday Malaysian bourse filing.Shares dropped about 2% in Tuesday's recent trade.The company had proposed a private placement of up to 10% of its total shares to third-party investors.
$KLSE:MAGMA